Warner Bros Officially Deems Paramount Bid Superior to Netflix
Warner Bros. Discovery has formally labeled Paramount Skydance’s all-cash bid superior to Netflix’s, kicking off a sh...
Articles — Page 2185
Plaintiff Says I Wanted Time: Social Media Trial Unfolds
A young plaintiff testifies in a civil trial accusing major platforms of harming mental health, focusing on a compuls...
Warner Bros. Discovery Deems Paramount Bid Superior
Warner Bros. Discovery has ruled Paramount's bid superior, setting a tight four-day window for Netflix to respond as ...
Butterfly (BFLY) 2025 Earnings: Outlook & Analysis
As butterfly (BFLY) prepares for 2025 earnings, investors want clarity on growth, margins, and cash runway. This arti...
Dorman (DORM) 2025 Earnings Outlook for Investors Today
Dorman's 2025 earnings narrative hinges on aftermarket demand, margins, and strategic bets. This guide breaks down wh...
GoodRx (GDRX) 2025 Earnings: A Practical Investor Guide
As GoodRx navigates evolving discount dynamics and a changing membership model, the 2025 earnings picture will hinge ...
Vericel (VCEL) 2025 Earnings: A Practical Investor Guide
A practical, investor-focused guide to vericel (vcel) 2025 earnings. Learn how revenue, margins, and milestones could...
Csenge Advisory Group Increased Its LMBS Stake in Q4
Csenge Advisory Group boosted its stake in the First Trust LMBS ETF during Q4, signaling confidence in short-duration...
Despite Plenty Positive News, Aptos Sinks Again Amid Turmoil
Aptos has seen a notable price drop even with multiple upbeat developments. This deep dive explains what’s driving th...
IonQ Skyrocketing Today Quantum Stock: Is It a Buy Now?
IonQ is making waves as its stock jumps amid a supportive but uncertain market for quantum-tech plays. This article b...
Perimeter Solutions Earnings: A Practical PRM Investor Guide
Investor-focused guide to perimeter solutions earnings. Learn how revenue, margins, and cash flow shape PRM stock pro...
Why Shares Novo Nordisk Stock Sank This Week: Key Factors
Novo Nordisk stock faced renewed selling pressure this week as investors weighed trial results and government-driven ...